We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Iovance Biotherapeutics Inc | NASDAQ:IOVA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.81 | 6.29% | 13.69 | 13.50 | 13.69 | 13.8799 | 13.30 | 13.46 | 4,292,824 | 01:00:00 |
From May 2019 to May 2024
In order to participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 1423064. The live webcast can be accessed under “News & Events” in the “Investors” section of the Company’s website at http://www.iovance.com/ or you may use the link: https://edge.media-server.com/m6/p/q7762k6j.
A replay of the call will be available from October 31, 2017 at 7:00 p.m. ET to November 30, 2017 at 8:30 p.m. ET. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 1423064. The archived webcast will be available for thirty days in the Investors section of Iovance Biotherapeutics’ website at http://www.iovance.com/.
About Iovance Biotherapeutics, Inc.Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent and metastatic or persistent cervical cancer. For more information, please visit http://www.iovance.com.
Investor Contact: Sarah McCabeStern Investor Relations, Inc.212-362-1200sarah@sternir.com
Media Contact:Evan Smith/Kotaro YoshidaFTI Consulting212-850-5622/212-850-5690 evan.smith@fticonsulting.comkotaro.yoshida@fticonsulting.com
1 Year Iovance Biotherapeutics Chart |
1 Month Iovance Biotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
